BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II
Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof Of Concept In Second Neuropathic Pain Study In Lumbosacral Radiculopathy 9/23/2014
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014
FibroGen, Inc.Announces One-Year Data Supporting The Safety And Efficacy Profile Of FG-3019 In Patients With Idiopathic Pulmonary Fibrosis 9/22/2014
DBV Technologies Announces Primary Endpoint Met In VIPES, Viaskin Peanut's Phase 2b Clinical Trial In Peanut Allergy 9/22/2014
AbbVie (ABBV) To Present Clinical Study Data On Potential New Oncology Medicines At The 2014 European Society Of Medical Oncology Annual Meeting 9/22/2014
Bio Blast Pharma Announces Initiation Of Its Canadian OPMD Clinical Study Center At McGill University, Montreal 9/22/2014
Progenics Pharmaceuticals, Inc. (PGNX) Presents Long Term Follow-Up Of Pivotal Phase 2 Trial Of Azedra In Malignant Pheochromocytoma 9/22/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS - Phase II Trial Results Published In The Leading Medical Journal Neurology 9/22/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS – Phase II Trial Results Published In The Leading Medical Journal Neurology 9/22/2014
Flexion Therapeutics (FLXN) Reports FDA Clinical Hold For Phase 2b Trial Of Osteoarthritis Drug 9/19/2014
Umecrine Mood Announces Positive Results From An Exploratory Phase I/II Study With UC1010 In Premenstrual Dysphoric Disorder (PMDD) 9/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Paediatric Patients With Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements In Growth And Physical Function 9/19/2014
Gilead Sciences, Inc. (GILD)'s Experimental Drug Simtuzumab Fails Mid-Stage Study 9/19/2014
OXiGENE (OXGN) Initiates Phase 2 Study Of Fosbretabulin In Gastrointestinal Neuroendocrine Tumors 9/18/2014
Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer 9/18/2014
ProSensa Holding N.V. (RNA) Announces Commencement Of Re-Dosing Of Drisapersen In North America In Patients With Duchenne Muscular Dystrophy 9/18/2014
Rebiotix Release: PUNCH CD Study Drug Targeting Recurrent C. Difficile Infection To Be Presented At IDWeek 2014 9/18/2014
Immune Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial In Ulcerative Colitis 9/18/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 9/18/2014
SWOG To Resume Clinical Trial Of Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 9/18/2014
Galapagos NV (GLPG.BR) Reports High Participation Rate In Long Term Extension Study With GLPG0634 In RA Patients 9/18/2014
Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial Of RSV F-Protein Nanoparticle Vaccine Candidate In Healthy Third-Trimester Pregnant Women 9/17/2014
BioBlast Pharma (ORPN) Announces Preclinical And Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study In OPMD 9/17/2014
Can-Fite BioPharma (CFBI)'s Drug CF101 Is Presented In Scientific Journal As One Of Four Small Molecule Drugs For The Treatment Of Psoriasis 9/17/2014
Neuraltus Pharmaceuticals, Inc.' ALS Treatment Candidate, NP001, Highlighted At ALS Research Group Summit 9/17/2014
Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows Positive Data In A Proof Of Concept Study 9/17/2014
Moberg Pharma AB (Formerly known as Moberg Derma) Announces Successful Results For MOB-015 In A Phase II Study For The Treatment Of Onychomycosis 9/17/2014
Amarantus BioSciences, Inc. Provides Program Update On Phase 2b Eltoprazine For Parkinson's Disease And Adult ADHD 9/17/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Overall And KRAS-Mutated Patient Data From U.S. Randomized Phase 2 Pancreatic Cancer Study 9/17/2014
AVANIR Pharmaceuticals (AVNR) Rockets As Lead Drug Succeeds In Reducing Alzheimer's Related Agitation; Stock Up 63.20% At 10:19AM ET On Monday 9/16/2014
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9/16/2014
Thrasos Therapeutics Announces Successful Formal Interim Analysis And Clinical Update For Phase 2 Study Of THR-184 For Acute Kidney Injury 9/16/2014
Ophthotech Corporation (OPHT) Announces Fovista® Phase 2b Independent Analysis Shows That Fovista® Anti-PDGF Therapy, Combined With Anti-VEGF Therapy, Is Associated With A Reduction Of Sub-Retinal Fibrosis In Wet AMD Patients 9/16/2014
NovaBiotics Ltd Receives Orphan Drug Status From FDA For Lynovex® For The Treatment Of Cystic Fibrosis 9/16/2014
Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 9/16/2014
Coldstream Laboratories Inc. Partners With CytImmune Sciences Inc. For Phase 2 Sterile Manufacturing 9/16/2014
Anergis Reports Positive Long-Term Clinical Efficacy Of Lead Compound AllerT 9/16/2014
Cardioxyl Pharmaceuticals Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 9/16/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Improved Survival Observed In Pediatric Patients With Severe Hypophosphatasia (HPP) Who Were Treated With Investigational Asfotase Alfa For Up To Five Years 9/15/2014
Cellprothera And BioCardia Partner On Phase 2 EXCELLENT Trial 9/15/2014
Lexicon Pharmaceuticals, Inc. (LXRX) Announces A Publication In The American Diabetes Association's Journal, Diabetes Care 9/12/2014
Amarantus BioSciences, Inc. Completes Enrollment Of 72 Patient LP-002 Clinical Study For Alzheimer's Blood Diagnostic Lympro Test® 9/12/2014
Genocea Biosciences Commences Phase 2a Trial For GEN-004, Universal Pneumococcal Vaccine Candidate 9/12/2014
Oxygen Biotherapeutics, Inc. (OXBT) Shares Gyrate After Halting Mid-Stage Brain Injury Trial 9/12/2014
Synthetic Biologics, Inc. (SYN) To Host Phase 2 Trimesta™ For Multiple Sclerosis Conference Call 9/11/2014
Prosonix Confirms The Potential Of Its Multi-Component Particle™ Technology For Developing Novel Inhaled Dual And Triple Combination Therapies For Respiratory Diseases 9/11/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled in Lucitanib Phase 2 Study In FGF-aberrant Advanced Breast Cancer 9/11/2014
Enanta Pharmaceuticals, Inc. Announces The Initiation Of Phase 2b Clinical Trial With Regimen Containing HCV Protease Inhibitor ABT-493 9/10/2014
Cellceutix (CTIX) Provides Initial Observations Of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application To FDA For Phase 2 Trial Of Brilacidin-OM For Oral Mucositis 9/10/2014
Symbiomix Therapeutics, LLC Makes First Corporate Announcement: Completion Of Enrollment In A Phase 2 Clinical Trial Of SYM-1219 For Bacterial Vaginosis 9/9/2014
AstraZeneca PLC (AZN)’s Phase 2 Lung Drug Data Gives Mixed Messages 9/9/2014
Serodus AS Announces Positive Phase Iia Results On SER100 In Patients With Systolic Hypertension 9/9/2014
Mimetogen Pharmaceuticals Announces Topline Results Of Its Second Clinical Study With MIM-D3 For The Treatment Of Dry Eye Syndrome 9/9/2014
Theravance, Inc. (THRX) Announces Positive Top-Line Results From Phase 2b Dose-Ranging Study Of Its Investigational LAMA, TD-4208, For The Treatment Of COPD 9/9/2014
C3 Jian, Inc. Completes Phase 2 Clinical Trial Of Anti-Cavity Drug 9/9/2014
Data On Chimerix, Inc. (CMRX)'s Brincidofovir Suggests Favorable Resistance Profile In Adenovirus And Cytomegalovirus (CMV) 9/9/2014
Seres Health Presents Final Data For Study Of SER-109 In Recurrent Clostridium Difficile Infection At ICAAC 2014 Conference 9/9/2014
Galena Biopharma  (GALE) Doses First Patient In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 9/9/2014
Scioderm To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The Debra International Congress 9/9/2014
Advaxis, Inc. Provides A Clinical Development Update For Its Immunotherapy, ADXS-HPV, For The Treatment Of Cervical Cancer 9/9/2014
ASLAN Pharmaceuticals Pte Ltd Doses First Patients In First Clinical Study In Taiwan 9/9/2014
Amarantus BioSciences, Inc. Announces Positive MANF Ocular Toxicology Data 9/9/2014
Mast Therapeutics (MSTX) Reports Positive Results From Phase 2 Pulmonary Arterial Hypertension Study 9/8/2014
Recro Pharma (REPH) Halts Pain Drug Study Due To Fault In Trial Design; Stock Tanks 9/8/2014
ProSensa Holding N.V. (RNA) Announces Lancet Neurology Publication Of An Exploratory Phase 2 Study (DEMAND II) Demonstrating Efficacy And Safety Of Drisapersen In Patients With Duchenne Muscular Dystrophy 9/8/2014
Sangamo BioSciences, Inc. (SGMO) Announces Presentation At ICAAC Of New Clinical Data Demonstrating Sustained Functional Control Of Viremia In Multiple HIV-Infected Subjects Treated With SB-728-T 9/8/2014
GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update At 8th International Liver Cancer Association Conference 9/8/2014
KemPharm, Inc. Advances KP201 Clinical Program With Initiation Of Human Abuse Liability And Human Gastrointestinal Motility Trials 9/8/2014
Pharmatech, Inc. Announces Research Collaboration Under Phase II National Cancer Institute/SBIR Grant With Weill Cornell Medical College 9/8/2014
European Medicines Agency Accepts TiGenix Pediatric Investigation Plan For Cx601 9/8/2014
Update On Invion Limited’s Phase II Study Of INV103 (Ala-Cpn10) In Lupus Patients 9/8/2014
PRANA Biotechnology (PRAN) Receives FDA Orphan Drug Designation For PBT2 For Huntington Disease 9/5/2014
SCRA Technology Ventures Company Publishes Phase 2 Clinical Trial Results 9/5/2014
TRACON Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial Of TRC105 In Patients With Soft Tissue Sarcoma 9/4/2014
Merck & Co., Inc. (MRK)’s Investigational Beta-Lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) And Fast Track Designations By FDA 9/4/2014
Kamada Ltd. (KMDA) Reports Final Results From Phase 2/3 Clinical Trial Of Inhaled Alpha-1 Antitrypsin To Treat Alpha-1 Antitrypsin Deficiency 9/4/2014
Alkermes plc (ALKS) Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic 9/3/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Phase 2 Trial - Successful Efficacy Results 9/3/2014
Nuvo Research Inc. (NRI.TO) Completes Enrollment In WF10™ Phase 2 Clinical Trial 9/3/2014
Edison Pharmaceuticals, Inc. Announces Phase 2 Positive Clinical Results For EPI-743 In Rett Syndrome 9/3/2014
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis 9/3/2014
Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies 9/3/2014
Arena Pharmaceuticals, Inc. (ARNA)' APD811 Granted Orphan Drug Status For Pulmonary Arterial Hypertension 9/3/2014
Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events 9/3/2014
Oncolytics Biotech Inc. (ONC.TO) Neuroderm Announces Start Of Phase 2a Study Of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration For Patients With Severe Parkinson's Disease 9/3/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Patient Enrollment In U.S. Randomized Phase 2 Ovarian Cancer Study 9/3/2014
AstraZeneca PLC (AZN) Pops On Possibility Of Another Pfizer (PFE) Bid; Start Of New Cancer Trial 9/2/2014
MediciNova, Inc. To Present Data On MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis (IPF) During The 18th International Colloquium On Lung And Airway Fibrosis (ICLAF) 9/2/2014
Conatus Pharmaceuticals Inc. Initiates Phase 2 Trial In Patients With Liver Cirrhosis And Separate Open Label Phase 2 Trial In Cirrhosis Patients With Portal Hypertension 9/2/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Adolescents With ADHD 9/2/2014
Cellular Biomedicine Group (CBMG) Launches Clinical Research Study For Cartilage Defect Stem Cell Therapy 9/2/2014
Nuvilex (NVLX) Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-In-A-Box® Treatment For Pancreatic Cancer 9/2/2014
Promedior Receives U.S. Orphan Drug Designation For PRM-151 For The Treatment Of Myelofibrosis 9/2/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Completes Enrollment In Randomized Phase 2 Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 9/2/2014
VentiRx Pharmaceuticals, Inc. Announces Fast Track Designation Granted For Motolimod (VTX-2337), A Novel Immunotherapy For Women With Ovarian Cancer 9/2/2014
Xention Limited Commences First Phase 2 Study Of XEN-D0103 In Atrial Fibrillation 9/2/2014
Dezima Pharma Reports Positive Results In Its Phase 2b TULIP Trial With CETP Inhibitor TA-8995 In Dyslipidemia 8/29/2014
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014
Pfizer Inc. (PFE)’s Investigational Vaccine Candidate For Clostridium Difficile Receives FDA Fast Track Designation 8/28/2014
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce Initiation Of Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 8/28/2014
Madison Vaccines To Be Used In Clinical Trial Of A New Combination Approach To Immunotherapy Funded By The Prostate Cancer Foundation And The Movember Foundation 8/28/2014
Auxilium Pharmaceuticals (AUXL) To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 8/28/2014
Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 8/27/2014
Gilead Sciences, Inc. (GILD) Shaky As Achillion Pharmaceuticals, Inc. (ACHN)'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial 8/27/2014
AVANIR Pharmaceuticals (AVNR) Announces Initiation Of Phase 2 Study Of AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 8/26/2014
Ruthigen Receives Recommendation From Data Monitoring Committee To Initiate Phase 1/2 Human Clinical Trial Of RUT58-60 8/26/2014
Profil Institute for Clinical Research, Inc. Reaches Milestone In Early Phase Clinical Research For Diabetes 8/26/2014
Anavex Life Sciences Corp. (AVXL.OB) Selects The Alfred Hospital In Melbourne, Australia As Lead Site For Phase 2a Alzheimer's Clinical Trial 8/26/2014
U.S. Army Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of PTSD With The NeuroSigma, Inc. eTNS System 8/25/2014
Pradaxa® (dabigatran etexilate mesylate) Data To Be Presented At European Society of Cardiology Congress 2014 8/25/2014
Look Out Auxilium Pharmaceuticals (AUXL), BioSpecifics Technologies Corporation (BSTC) Also Touts Positive Data From Phase 2a Study Of CCH For Cellulite 8/22/2014
Auxilium Pharmaceuticals (AUXL) Drug Found Effective Against Cellulite In Phase 2 Study 8/22/2014
NovaBay Pharmaceuticals, Inc. (NBY) Reports NVC-422 Missed Endpoints In Phase 2 Study 8/21/2014
Boston Therapeutics, Inc. Completes Enrollment Of Patients With Type 2 Diabetes In Phase IIb Study On BTI-320 In The U.S. 8/20/2014
Cellceutix (CTIX) Completes Enrollment In Phase 2b Clinical Trial Of Brilacidin For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 8/19/2014
MediciNova, Inc. Shows Off Positive Phase 2a Study Of Ibudilast 8/19/2014
iCo Therapeutics Inc. Announces Positive Oral Amphotericin B Study Results 8/19/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
Celator Pharmaceuticals, Inc. Initiates Pharmacokinetic And Pharmacodynamics Clinical Study Of CPX-351 8/19/2014
DelMar Pharmaceuticals Provides Update On Glioblastoma Clinical Trial And Results Of Warrant Tender Offer 8/19/2014
Innate Immunotherapeutics’s Phase 2B Clinical Trial On SPMS To Start Recruiting Patients Following Perth Site Obtaining Ethics Approval 8/19/2014
Blanchette Rockefeller Neurosciences Institute Release: Human Brain Deficits Of PKCe: Targeted For Alzheimer's Disease Therapeutic And Diagnostic Trials 8/18/2014
Data Published By Researchers From The Scripps Research Institute Demonstrate Potential For MYC Inhibitor Licensed By Sorrento Therapeutics, Inc. 8/18/2014
Egalet Announces Successful End-Of-Phase 2 Meeting With The FDA For Egalet-002 8/18/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Publication By KaloBios Pharmaceuticals, Inc. (KBIO) And Collaborators Shows EphA3 As Target For Highly Selective Anticancer Therapy 8/14/2014
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study 8/14/2014
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/13/2014
Ohr Pharmaceutical (OHRP) Announces Additional Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data In Wet-AMD; The IMPACT Study 8/13/2014
Cellular Biomedicine Group (CBMG) Completes Patient Treatment In Phase 2b Clinical Trial For Rejoin™ Therapy For Knee Osteoarthritis 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Esperion Therapeutics, Inc. (ESPR) Provides Etc-1002 Development Program Update; Reports Second Quarter 2014 Financial Results 8/12/2014
Biodel Inc. (BIOD)'s Insulin Drug Found Effective In Phase 2 Trial 8/11/2014
Ohr Pharmaceutical (OHRP) Announces Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data in Retinal Vein Occlusion 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Mirati Therapeutics  (MRTX) Receives Orphan Designation From U.S. FDA For Mocetinostat In Diffuse Large B-Cell Lymphoma 8/11/2014
Celladon Corporation Announces Trial To Investigate MYDICAR In Patients With Heart Failure And LVAD 8/11/2014
Xenetic Biosciences Announces Ongoing Safety And Efficacy Data From Phase 2 Trial Of Erepoxen(R) 8/11/2014
BioSpecifics Technologies Corporation (BSTC) Announces Initiation Of Phase 2 Clinical Study Of CCH For Treatment Of Lipoma 8/8/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Oral Presentation Of CytRx Corporation (CYTR)’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology 8/7/2014
Symphogen A/S Release: Sym004 Advances Into Two New Clinical Trials And Receives Milestone Payments 8/7/2014
Neurovance Completes Enrollment In Human Abuse Liability Study For Centanafadine (Formerly Called EB-1020) For Adult ADHD 8/7/2014
San Diego's Cytori Therapeutics, Inc. (CYTX) Crashes As Safety Concerns Suspend Athena Trials 8/7/2014
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001 8/6/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Cara Therapeutics, Inc. (CARA) Initiates Proof-Of-Concept Phase 2 Trial Of I.V. CR845 In Uremic Pruritus 8/6/2014
Synthetic Biologics, Inc. (SYN) On Track To Initiate Clinical Program For SYN-004 To Protect Against C. difficile 8/5/2014
Atox Bio Release: AB103 Granted Orphan Medicinal Product Designation In The European Union For The Treatment Of Necrotizing Soft Tissue Infections (NSTI) 8/5/2014
Ophthotech Corporation (OPHT) Initiates First Of Several Expansion Studies To Further Evaluate Fovista® (Anti-PDGF) Therapy In Patients With Wet Age-Related Macular Degeneration 8/5/2014
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce First Patient Dosed In Phase 2 Study Of VPD-737 In Prurigo Nodularis 8/4/2014
Cellceutix (CTIX) Believes Brilacidin On Track To Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment In Phase 2b Trial For Acute Bacterial Skin And Skin Structure Infections Expected This Month 8/4/2014
Final Patient Treated In NeuralStem Inc. Phase II ALS Stem Cell Trial 8/4/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies 8/4/2014
NPS Pharmaceuticals, Inc. (NPSP) Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH) 8/4/2014
Novartis AG (NVS) Malaria Pill KAE609 Shows Promise As Best Drugs Fail 8/1/2014
Biota Pharmaceuticals, Inc. (BOTA) Stock Crashes As Influenza Drug Laninamivir Octanoate Fails Mid-Stage Trial; Stock Down -20.54% At 11:37AM ET 8/1/2014
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV 7/31/2014
Expanded Data On Disability And Cognitive Improvements In Phase 2 Study Of Synthetic Biologics, Inc. (SYN)' Trimesta™ In Multiple Sclerosis To Be Presented At 2014 Joint ACTRIMS-ECTRIMS Meeting 7/31/2014
NOXXON Pharma AG Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hyporesponsive Anemia 7/31/2014
Kala Pharmaceuticals Initiates Phase 2 Clinical Trial To Evaluate LE-MPP (KPI-121) In Patients With Retinal Vein Occlusion And Diabetic Macular Edema 7/31/2014
Immune Pharmaceuticals, Inc. Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 7/30/2014
RXi Pharmaceuticals (RXII) Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars 7/30/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014
EMD Serono Initiates Phase 2 Study Of Anti-PD-L1 Antibody MSB0010718C In Metastatic Merkel Cell Carcinoma 7/29/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
Neurotrope Initiates Phase 2a Study Of Bryostatin For The Treatment Of Alzheimer's Disease - Doses First Patients 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
Medivir AB (MVRBF): Phase II COSMOS Study Results Published In Lancet On World Hepatitis Day 7/28/2014
Phase 2 COSMOS Study Results Published In The Lancet Demonstrate Efficacy And Safety Of Janssen’s Once-Daily Simeprevir In All Oral 12-Week Combination With Sofosbuvir For Genotype 1 Chronic Hepatitis C 7/28/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase II Study Of ERY-ASP In Pancreatic Cancer 7/28/2014
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014
Esperion Therapeutics, Inc. (ESPR) Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/24/2014
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) 7/24/2014
Celsion Corporation (CLSN) Announces Positive Interim Data Update From Its Phase 2 DIGNITY Study In Breast Cancer 7/24/2014
Innapharma: Completion Of Target Enrollment In The Phase 2 EffiKIR Trial 7/24/2014
Inovio Pharmaceuticals (INO) HPV Immunotherapy Achieves Primary Efficacy Endpoint In Randomized Phase 2 Cervical Dysplasia Trial 7/23/2014
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/23/2014
Biotron Limited (BIT:AU) BIT225 Reverses HIV-Induced Impairment Of The Immune System 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
Advaxis, Inc. And MedImmune (AZN) Partner On Immuno-Oncology Combination Clinical Trial 7/22/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
Halozyme Therapeutics, Inc. (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Genocea Biosciences Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy 7/21/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With Enmd-2076 For Triple-Negative Breast Cancer In China 7/21/2014
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 7/21/2014
Anavex Life Sciences Corp. (AVXL.OB) Achieves Key Milestone As It Secures Cgmp Manufacturing For Drug Candidate Trial Supplies 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014